UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

6016 POSTER A novel organic arsenic S-dimethylarsino-glutathione (ZIO-101) experience in hematological malignancies

European journal of cancer supplements, 2007, Vol.5 (4), p.349-350

2007

Volltextzugriff (PDF)

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials

Cancer management and research, 2015-01, Vol.7 (default), p.83-92

2015

Volltextzugriff (PDF)

PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)

HemaSphere, 2019-06, Vol.3 (S1), p.319-n/a

2019

Volltextzugriff (PDF)

PF703 LONG‐TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM

HemaSphere, 2019-06, Vol.3 (S1), p.306-n/a

2019

Volltextzugriff (PDF)

5PSQ-117 Failure mode and effects criticality analysis: multicentric application on cancer chemotherapy process

European journal of hospital pharmacy. Science and practice, 2018-03, Vol.25 (Suppl 1), p.A218-A219

2018

Volltextzugriff (PDF)

Temperature- and volume-dependent dissolution of amifostine 500 mg reconstituted for subcutaneous injection in normal saline or sterile water for injection

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3207-3207

2005

Volltextzugriff (PDF)

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Annals of oncology, 2019-10, Vol.30 (10), p.1613

2019

Volltextzugriff (PDF)

A phase I/II study of oral melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e18574-e18574

2011

Volltextzugriff (PDF)

S853 SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW‐UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES

HemaSphere, 2019-06, Vol.3 (S1), p.380-381

2019

Volltextzugriff (PDF)

A preliminary report of a phase II trial of single-agent vinflunine as second-line treatment of advanced non-small cell lung cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.18156-18156

2007

Volltextzugriff (PDF)

Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8070-8070

2011

Volltextzugriff (PDF)

A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8134-8134

2010

Volltextzugriff (PDF)

The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e13555-e13555

2011

Volltextzugriff (PDF)

Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.10540-10540

2010

Volltextzugriff (PDF)

A phase II trial of single-agent vinflunine as second-line treatment for advanced non-small cell lung cancer (An International Oncology Network Study, #I-05–009)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.19033-19033

2008

Volltextzugriff (PDF)

A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network study, #I-04–015)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.19018-19018

2008

Volltextzugriff (PDF)

A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3064-3064

2011

Volltextzugriff (PDF)

Palonosetron (PALO), administered orally or intravenously (IV), plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.20608-20608

2008

Volltextzugriff (PDF)

A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.18025-18025

2007

Volltextzugriff (PDF)

Novel organic arsenic molecule darinaparsin: Development of IV and oral forms

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8501-8501

2009

Volltextzugriff (PDF)

Gemcitabine plus paclitaxel and gemcitabine plus docetaxel in first- or second-line metastatic breast cancer: A phase II randomized trial

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.1046-1046

2007

Volltextzugriff (PDF)

Salmonella typhimurium enteritis and bacteremia in the acquired immunodeficiency syndrome

Annals of internal medicine, 1985-02, Vol.102 (2), p.207

1985

Volltextzugriff (PDF)

Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP)

International journal of radiation oncology, biology, physics, 2004-09, Vol.60 (1), p.302-309

2004

Volltextzugriff (PDF)

Marked improvement in bone mineral density (BMD) for patients (pts) with monoclonal gammopathy of undetermined significance (MGUS) using zoledronic acid (ZOL)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.8550-8550

2008

Volltextzugriff (PDF)

A hemolytic-uremic syndrome with the acquired immunodeficiency syndrome

Annals of internal medicine, 1984-11, Vol.101 (5), p.716

1984

Volltextzugriff (PDF)

26 – 50 von 596

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(428)
Mit Volltextzugriff
(403)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(338)
Life Sciences & Biomedicine
(191)
Humans
(170)
Technology
(140)
Engineering
(128)
Engineering, Electrical & Electronic
(127)
Female
(111)
Male
(111)
Middle Aged
(84)
Adult
(68)
Biological And Medical Sciences
(66)
Aged
(59)
Medical Sciences
(53)
Oncology
(43)
Microwave Antennas
(40)
Risk Factors
(34)
Antennas
(33)
Microwave Measurement
(27)
Public Health
(27)
Adolescent
(26)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

6016 POSTER A novel organic arsenic S-dimethylarsino-glutathione (ZIO-101) experience in hematological malignancies

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials

PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)

PF703 LONG‐TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM

5PSQ-117 Failure mode and effects criticality analysis: multicentric application on cancer chemotherapy process

Temperature- and volume-dependent dissolution of amifostine 500 mg reconstituted for subcutaneous injection in normal saline or sterile water for injection

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

A phase I/II study of oral melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM)

S853 SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW‐UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES

A preliminary report of a phase II trial of single-agent vinflunine as second-line treatment of advanced non-small cell lung cancer

Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial

A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM)

The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors

Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial

A phase II trial of single-agent vinflunine as second-line treatment for advanced non-small cell lung cancer (An International Oncology Network Study, #I-05–009)

A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network study, #I-04–015)

A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies

Palonosetron (PALO), administered orally or intravenously (IV), plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV)

A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer

Novel organic arsenic molecule darinaparsin: Development of IV and oral forms

Gemcitabine plus paclitaxel and gemcitabine plus docetaxel in first- or second-line metastatic breast cancer: A phase II randomized trial

Salmonella typhimurium enteritis and bacteremia in the acquired immunodeficiency syndrome

Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP)

Marked improvement in bone mineral density (BMD) for patients (pts) with monoclonal gammopathy of undetermined significance (MGUS) using zoledronic acid (ZOL)

A hemolytic-uremic syndrome with the acquired immunodeficiency syndrome

Suchergebnisse filtern